Sun Pharma to acquire Organon for $11.75B enterprise value; stockholders to receive $14/share cash. Deal expected to close early 2027 pending approvals.
Sun Pharma has signed a definitive agreement to acquire Organon, with Organon stockholders to receive $14.00 per share in cash. The deal values Organon at an enterprise value of $11.75 billion and is expected to close in early 2027, subject to regulatory and stockholder approvals.
What happened
Sun Pharma has signed a definitive agreement to acquire Organon, with Organon stockholders to receive $14.00 per share in cash. The deal values Organon at an enterprise value of $11.75 billion and is expected to close in early 2027, subject to regulatory and stockholder approvals.
Quick reaction
One tap helps tune what we surface next.
Reader discussion
Public commentsNo comments yet. Start the discussion around this signal.
Follow this signal
Get updates on this story
We will email you if this changes materially. No spam. Daily brief optional.
Map context
See this on the live map
Keep the story in context with nearby live signals, countries, and category movement.
Related coverage
More story pages
Bank of England to war-game energy price shock scenarios this week. The central bank is expected to simulate responses to a prolonged energy crisis while holding off on immediate interest rate changes.
The Bank of England is expected to war-game multiple scenarios this week to determine its reaction to a prolonged energy price shock, while it holds off on immediate interest rate action.
Emerging-market equities hit record high as AI optimism and Iran's Strait of Hormuz proposal boost sentiment.
Emerging-market equities reached a record high, supported by optimism over artificial intelligence and a report that Iran has proposed a new plan to reopen the Strait of Hormuz.
Budget airlines seek $2.5 billion in government aid, WSJ reports. Frontier and Avelo are among those seeking funds in exchange for warrants convertible to equity stakes.
Budget airlines, including Frontier and Avelo, are reportedly seeking $2.5 billion in government aid in exchange for warrants that could convert into equity stakes, the Wall Street Journal reports.
China is tightening approvals for overseas borrowings, forcing companies to scramble for cash with about $100 billion of bonds maturing this year.
China is tightening approvals for overseas borrowings, causing some companies to urgently seek cash as approximately $100 billion in bonds are set to mature this year.
More live signals
Continue with the live feed.
The fastest nearby updates load from the public feed, not the enriched story endpoint.